- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05529251
De-escalation Study for Stage IIa/IIb < 3 cm Seminoma (EDEN)
Prospective Therapeutic De-escalation and miRNA-M371 Biomarker Evaluation Phase II Study for Stage IIa/IIb < 3 cm Seminomas
Phase II, multicenter, prospective, randomized, non-comparative, de-escalation study.
Patients with stage IIa/IIb < 3 cm seminoma histologically proved after orchiectomy will be included in the study and will receive 1 cycle of Etoposide Cisplatine (EP) chemotherapy.
Patients with negative week-3 PET-scan after the EP cycle, will be randomized (1:1 ratio, stratification according to the disease stage (stage IIa versus IIb seminoma)) to receive either radiotherapy (RT) boost on lymph nodes or 1 cycle of carboplatin AUC7 chemotherapy.
Patients with positive week-3 PET-scan will received 3 additional cycles of EP chemotherapy.
In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.
Study Overview
Status
Intervention / Treatment
Detailed Description
Stage II seminoma is defined by the presence of retroperitoneal lymph node metastases. It concerns approximately 15% of patients with seminoma. The standard treatment for patients with stage IIa/b seminoma, after orchiectomy, is extended lumbo-aortic/ipsilateral iliac radiotherapy (RT). Performing chemotherapy (CT) with 3 courses of Bleomycin-Etoposide-Cisplatin (BEP) or 4 courses of Etoposide-Cisplatin (EP) is an alternative.
The optimal treatment choice remains controversial. Both treatment modalities are associated with excellent efficacy but also acute and late toxicities. European Society of Medical Oncology (ESMO) guidelines recommended in equal measure CT and RT for stage IIa. A recent systematic review concluded that RT and cisplatin-based combination CT are equally effective in clinical stage IIa/IIb seminoma, with a trend in favor of chemotherapy in stage IIb because of lower relapse rate. However, due to the rarity of stage II seminoma, a sufficiently powered randomized trial comparing radiotherapy with chemotherapy is unlikely to be completed.
De-escalation strategies are required to minimize acute and long-term toxicities while maintaining efficacy. De-escalated treatment for seminoma patients with stage IIb/IIC/III and good prognosis according to International Germ Cell Cancer Collaborative Group (IGCCCG), based on negative PET after 2 cycles of EP chemotherapy, is feasible and safe according to SEMITEP results (cohort 2). In case of negative PET, 1 additional cycle of CT with carboplatin AUC7 was administered.
Furthermore, serum levels of microRNA (miR)-371a-3p (miRNA-M371) have been significantly associated with clinical stage, primary tumor size and response to treatment in testicular germ cell tumors, with sensitivity and specificity higher than those of classic markers (hCGt, LDH). However, further evaluations are needed before modifying clinical practices.
We propose to conduct a multicenter, prospective, randomized, non-comparative, de-escalation phase II study in patients with stage IIa/IIb seminoma < 3 cm, evaluating:
- a more de-escalated CT treatment: 1 cycle of EP followed, in case of negative PET, by either a boost of RT on lymph node or 1 cycle of carboplatin AUC7
- the biomarker miRNA-M371 in therapeutic decision and correlation with PET.
In parallel, eligible patients scheduled to receive standard lombo-aortic RT will be registered in an observational cohort.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ellen BLANC
- Phone Number: +33 4 78 78 29 67
- Email: ellen.blanc@lyon.unicancer.fr
Study Contact Backup
- Name: Aude FLECHON, Dr
- Phone Number: + 33 4 78 78 26 43
- Email: aude.flechon@lyon.unicancer.fr
Study Locations
-
-
-
Besançon, France
- Not yet recruiting
- CHU Besançon
-
Contact:
- Elodie KLAJER
- Email: elodie.klajer@gmail.com
-
Bordeaux, France
- Recruiting
- CHU Bordeaux
-
Contact:
- Marine GROSS-GOUPIL
- Email: marine.gross-goupil@chu-bordeaux.fr
-
Caen, France
- Recruiting
- Centre François Baclesse
-
Contact:
- Florence JOLY
- Email: f.joly@baclesse.unicancer.fr
-
Clermont-Ferrand, France
- Recruiting
- Centre Jean Perrin
-
Contact:
- Hakim MAHAMMEDI
- Email: hakim.mahammedi@clermont.unicancer.fr
-
Lille, France
- Recruiting
- Centre Oscar Lambret
-
Contact:
- Thomas RYCKEWAERT
- Email: t-ryckewaert@o-lambret.fr
-
Sub-Investigator:
- Aurélien CARNOT
-
Limoges, France
- Recruiting
- CHU de Limoges
-
Contact:
- Julia PESTRE MUNIER
- Email: julia.munier-pestre@chu-limoges.fr
-
Sub-Investigator:
- Valérie LE BRUN-LY
-
Lyon, France
- Recruiting
- Centre Léon Berard
-
Contact:
- Aude FLECHON
- Email: aude.flechon@lyon.unicancer.fr
-
Sub-Investigator:
- Armelle VINCENEUX
-
Marseille, France
- Recruiting
- Institut Paoli Calmettes
-
Contact:
- Gwenaëlle GRAVIS
- Email: gravisg@ipc.unicancer.fr
-
Sub-Investigator:
- Slimane DERMECHE
-
Sub-Investigator:
- Mathilde GUERIN
-
Sub-Investigator:
- Cécile VICIER
-
Nice, France
- Recruiting
- Centre Antoine Lacassagne
-
Contact:
- Agnès DUCOULOMBIER
- Email: agnes.ducoulombier@nice.unicancer.fr
-
Sub-Investigator:
- Delphine BORCHIELLINI
-
Paris, France
- Not yet recruiting
- Hopital Saint Louis
-
Contact:
- Stéphane CULINE
- Email: stephane.culine@sls.aphp.fr
-
Sub-Investigator:
- Clément DUMONT
-
Sub-Investigator:
- Tiphaine LAMBERT
-
Saint-Herblain, France
- Recruiting
- ICO René Gauducheau
-
Contact:
- Emmanuelle BOMPAS
- Email: emmanuelle.bompas@ico.unicancer.fr
-
Sub-Investigator:
- Frédéric ROLLAND
-
Suresnes, France
- Not yet recruiting
- Hopital Foch
-
Contact:
- Christine ABRAHAM
- Email: c.abraham@hopital-foch.com
-
Toulouse, France
- Recruiting
- Institut Universitaire de Cancer de Toulouse (IUCT-O)
-
Sub-Investigator:
- Thibaud VALENTIN
-
Sub-Investigator:
- Loïc MOUREY
-
Sub-Investigator:
- Damien POUESSEL
-
Contact:
- Christine CHEVREAU
- Email: chevreau.christine@iuct-oncopole.fr
-
Vandœuvre-lès-Nancy, France
- Not yet recruiting
- Institut de Cancérologie de Lorraine
-
Contact:
- Lionel GEOFFROIS
- Email: l.geoffrois@nancy.unicancer.fr
-
Sub-Investigator:
- Camille SIMON
-
Sub-Investigator:
- Vincent MASSART
-
Villejuif, France
- Recruiting
- Institut Gustave Roussy
-
Contact:
- Pierre BLANCHARD
- Email: pierre.blanchard@gustaveroussy.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria :
- Age ≥ 18 years on the day of signing informed consent.
- Primary testicular seminomatous germ cell tumor.
- Stage IIa/IIb < 3 cm in largest diameter seminoma, histologically proved after orchiectomy.
- Confirmation of a progressive disease (positive PET scan or increase of lymph nodes size by two successive CT scan).
- Good prognosis according to IGCCCG and LDH < 2.5 x Upper Limit of Normal (ULN).
- Normal alpha-fetoprotein (AFP) before and after orchiectomy.
- No prior treatment with radiotherapy or chemotherapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤ 2.
Adequate bone-marrow, hepatic, and renal functions with:
- Neutrophils ≥ 1.5 x Giga/l, platelets ≥ 100 x Giga/l,
- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤ 1,5 x ULN,
- Serum creatinine < 140 µmol/l OR calculated clearance > 60 ml/min (using either Cockcroft-Gault formula or Modification of Diet in Renal Disease (MDRD) for > 65 years old),
- Direct and total bilirubin ≤ ULN.
- Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
- Accepting to use effective contraceptive measures or abstain from heterosexual activity, for the course of the study and through 12 months after the last dose of chemotherapy or being surgically sterile. All patients should seek advice regarding cryoconservation of sperm prior treatment initiation because of the possibility of infertility
- Affiliation to a health insurance.
- Signed and dated informed consent.
Non-exclusion criteria :
- Extra-retroperitoneal metastasis on Computed tomography scan (CT scan).
- Infection by Human Immunodeficiency Virus (HIV), or active infection with the Hepatitis B or C virus.
- History, within 2 years, of cancer other than seminoma, except for treated skin cancer (basal cell).
- Uncontrolled or severe cardiovascular pathology.
- Uncontrolled or severe hepatic pathology.
- Patient deprived of liberty or requiring tutorship or curatorship.
- Psychological, physical, sociological, or geographical conditions that would limit compliance with study protocol requirements (at the investigator's discretion).
- Participation to another clinical trial, except for supportive care trials.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ARM A
RADIOTHERAPY boost 20 to 30 Gy on lymph nodes
|
Radiotherapy boost 20 to 30 Gy, in daily 2 Gy fractions and 5 fractions per week :
|
Experimental: ARM B
One cycle of CARBOPLATIN AUC7
|
Carboplatin at dose (mg) = AUC7 (mg/ml x min) x (DFG ml/min + 25)
|
Other: ARM C
3 cycles of ETOPOSIDE and CISPLATIN
|
3 Cycles of EP chemotherapy, administred every 3 weeks following standard practice
|
No Intervention: OBSERVATIONAL COHORT
STANDARD RADIOTHERAPY on lymph nodes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PFR-36M
Time Frame: Up to 36 months after inclusion
|
Progression-free rate at 36 months The PFR-36M is assumed to be a random variable following a binomial distribution Bin (n, p) where n is the sample size and p is the true underlying PFR-36M. Conclusions and inferences will be conducted on p. The prior distribution of p (representing the knowledge of the progression-free rate probability prior to observing the data) will be pre-specified. In the absence of a strong idea about the PFR-36M to be observed, a non-informative prior distribution Beta (1,1) will be considered. Pr[PFR-36M ≥ 80%] will be expressed in each arm, associated with its 95% credibility interval. A treatment arm will be considered a positive sign for efficacy of de-escalation if there is a high probability that PFR-36M will be higher or equal to 80%: Pr[PFR-36M ≥ 80%] ≥ 90%. It means that if most of the distribution (90% of it) falls to the right hand side of 80%, it indicates that it is very likely that the effect is at least 80% |
Up to 36 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
miRNA-M371
Time Frame: Up to 5 years
|
Serum level of miRNA-M371 as a potential biomarker of response.
Association between serum level of miRNA M371 and response to treatments (according to RECIST v1.1) will be evaluated using a non-parametric Wilcoxon Mann and Whitney test and describe with boxplots.
|
Up to 5 years
|
Association of PET scan results and miRNA-M371 rate
Time Frame: Up to 5 years
|
Correlation between serum level of miRNA M371 and FDG-PET results (metabolic response) will be evaluated using the Kendall rank correlation and describe graphically.
|
Up to 5 years
|
Overall survival (OS)
Time Frame: Up to 3 years
|
The Overall Survival will be defined as the time from date of inclusion to the date of death, from any cause. Patient whose death is not known at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive. The Kaplan-Meier (KM) approach will be used to estimate median OS. Median OS as well as Survival rates at specific timepoints will be presented together with their 95% confidence interval (CI). |
Up to 3 years
|
Quality of life (QoL)
Time Frame: Up to 20 months
|
The QoL will be assessed using the EORTC QLQ-C30 questionnaire.
|
Up to 20 months
|
Tolerance to treatment
Time Frame: Up 5 years
|
The tolerance to each treatment will be described mainly on the frequency of adverse events (AEs) and their intensity and severity determined using the National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) grading scale version 5. Descriptive statistics will be provided for characterizing and assessing patient tolerance to treatment. AEs will be described and coded, in total and per System Organ Class and Preferred Term with Medical Dictionary for Regulatory Activities (MedDRA) coding |
Up 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aude FLECHON, Dr, Centre Leon Berard (Lyon, France)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EDEN (ET21-344)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Seminoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)Active, not recruitingLymphadenopathy | Stage I Testicular Seminoma | Stage II Testicular SeminomaUnited States
-
University Health Network, TorontoRecruitingStage II Testicular Seminoma | Lymphadenopathy RetroperitonealCanada
-
Barts & The London NHS TrustUniversity College London HospitalsCompletedMetastatic SeminomaUnited Kingdom
-
Abramson Cancer Center of the University of PennsylvaniaMassachusetts General HospitalCompleted
-
Tata Memorial CentreNot yet recruiting
-
Gustave Roussy, Cancer Campus, Grand ParisRecruiting
-
Swiss Group for Clinical Cancer ResearchActive, not recruiting
-
Heinrich-Heine University, DuesseldorfRecruiting
-
Daiichi Sankyo, Inc.TerminatedNon-CNS Germ Cell Tumors (Seminomas and Nonseminomas)United States, France, United Kingdom
-
Memorial Sloan Kettering Cancer CenterAstraZenecaActive, not recruitingNonseminomatous Germ Cell Tumor | Seminoma | Germ Cell Tumor | Dysgerminoma | Pineal Germ Cell Tumor | Germinomatous Germ Cell TumorUnited States
Clinical Trials on Radiotherapy boost
-
St George Hospital, AustraliaUnknown
-
University College, LondonNational Institute for Health Research, United KingdomUnknownEarly Breast CancerFrance, Korea, Republic of, United Kingdom, Italy, United States, China, Malaysia, Saudi Arabia, South Africa, Spain, Switzerland, Thailand
-
The Greater Poland Cancer CentreCompletedProstate CancerPoland
-
The Clatterbridge Cancer Centre NHS Foundation...Completed
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Prognostic Stage I Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Maria Sklodowska-Curie National Research Institute...RecruitingRecurrent Soft Tissue Sarcoma | Recurrent Sarcoma | Radiation Induced Neoplasms | Radiation-Induced CancerPoland
-
University Health Network, TorontoRecruiting
-
Zhongnan HospitalUnknown
-
Emory UniversityCompleted
-
University Hospital, EssenUnknown